Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.

Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J. · 2018

Read Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. by Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5854542.txt.

Introduction

Ma and co-authors report a pan-cancer study of 1,699 childhood cancers. Their article appeared in Nature. The set covers leukemias and solid tumours across six types. The team used whole-genome, whole-exome, and RNA sequencing. Samples came from children enrolled in Children's Oncology Group trials. All data passed through one shared analysis framework.

The team reports 142 driver genes in these childhood cancers. Only 45 percent matched drivers found in adult cancers. Copy number changes and structural changes made up most events. The team also found eleven mutation signatures, one tied to sunlight. Their data stress that childhood cancers need their own precision therapies. Readers get the full genomic picture across these tumour types.

Catalog record

CREATORMa X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5854542

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Pan-cancer genome and transcriptome analyses of 1,699 pediatric leukemias and solid tumors By Xiaotu Ma, Yu Liu, Yanling Liu, Ludmil B Alexandrov, Michael N. Edmonson, Charles Gawad, Xin Zhou, Yongjin Li, Michael C. Rusch, John Easton, Robert Huether, Veronica Gonzalez-Pena Published in: Nature DOI: 10.1038/nature25795 ABSTRACT SUMMARY Analysis of molecular aberrations across multiple cancer types, known as pan-cancer analysis, identifies commonalities and differences in key biological processes dysregulated in cancer cells from diverse lineages. Pan-cancer analyses have been performed for adult1–4 but not pediatric cancers, which commonly occur in developing mesodermic rather than adult epithelial tissues5. Here we present a pan-cancer study of somatic alterations, including single nucleotide variants (SNVs), small insertion/deletions (indels), structural variations (SVs), copy number alterations (CNAs), gene fusions and internal tandem duplications (ITDs), in 1,699 pediatric leukemia and solid tumours across six histotypes, with whole-genome (WGS), whole-exome (WES) and transcriptome (RNA-seq) sequencing data processed under a uniform analytical framework (Online Methods and Extended Data Fig. 1). We report 142 driver genes in pediatric cancers, of which only 45% matched those found in adult pan-cancer studies and CNAs and SVs constituted the majority (62%) of events. Eleven genome-wide mutational signatures were identified, including one attributed to ultraviolet-light exposure in eight aneuploid leukemias. Transcription of the mutant allele was detectable for 34% of protein-coding mutations, and 20% exhibited allele-specific expression. These data provide a comprehensive genomic architecture for pediatric cancers and emphasize the need for pediatric cancer-specific development of precision therapies. MAIN TEXT Paired tumour and normal samples of 1,699 pediatric cancers from patients enrolled in Children’s Oncology Group clinical trials were analyzed, including 689 B-lineage acute lymphoblastic leukemias (B-ALL), 267 T-lineage ALL (T-ALL), 210 acute myeloid leukemias (AML), 316 neuroblastoma (NBL), 128 Wilms tumour (WT) and 89 osteosarcoma (OS) (Extended Data Fig. 1a–c). All tumour specimens were obtained at initial diagnosis, and 98.5% of patients were 20 years or younger (Methods, Extended Data Fig. 1d). The median somatic mutation rate ranged from 0.17 per million bases (MB) in AML and WT to 0.79 in OS (Fig. 1a–b), lower than the 1–10/MB in common adult cancers6. Genome-wide analysis (Methods) identified 11 mutational signatures (T-1 through T-11; Fig. 1c–e and Supplementary Table 1a–c). T-1 through T-9 corresponded to known COSMIC signatures7, whereas T-10 and T-11 were novel but enriched in mutations with a low (<0.3) mutant allele fraction (MAF). T-1 and T-4 (clock-like endogenous mutational processes) were present in all samples and contributed to large proportions of all mutations in T-ALL (97%), AML (63%), B-ALL (36%), and WT (28%). T-2 and T-7 (APOBEC) were highly enriched in B-ALLs with ETV6-RUNX1 fusions (15-fold and 9-fold enrichment for T-2 and T-7, respectively; Supplementary Table 1e). T-3 (homologous recombination deficiency) was present in many childhood cancers, including OS (18/19), NBL (59/137), WT (28/81), and B-ALL (47/218). T-8 (8-oxoguanine DNA damage) was present in a small proportion (4.5%–12%) of AML, B-ALL, OS, and WT samples. T-8 was also present in many (36%) NBL samples and was associated with age at diagnosis (Supplementary Table 1d). T-9 (DNA repair deficiency) was present in two B-ALLs, including one (sample PARJSR) with a somatic MSH6 frameshift mutation. T-2, T-3, T-5, T-7, T-8, and T-9 were enriched among the 39 samples with elevated mutation rates in each histotype (Fig. 1d). The T-5 UV-exposure signature was unexpectedly present in eight B-ALL samples (Extended Data Fig. 2a–c). Although its mutation rate in B-ALL, ranging from 0.06 to 0.72 per MB, was 100-fold lower than the average rate in adult (15.8/MB)8 and pediatric (14.4/MB)9 skin cancer, T-5 exhibited other features associated with UV-related DNA damage. Specifically, CC>TT dinucleotide mutations were enriched 110-fold in these 8 B-ALLs versus other samples (P=1.07×10−7), which is consistent with pyrimidine dimer formation. Moreover, transcriptional strand bias in T-5 indicated that photodimer formation contributed to cytosine damage. The validity of T-5 was further confirmed by analysis of mutation clonality, cross-platform concordance, genomic distribution and mutation spectra of each sample (Methods, Extended Data Fig. 2d–i), indicating that UV exposure or other mutational processes10,11 may contribute to pediatric leukemogenesis. Intriguingly, all T-5 B-ALLs had aneuploid genomes (P=3×10−5; two-sided binomial test; cohort frequency 24%) without any oncogenic fusions. By analyzing enrichment12,13 of somatic alterations within each histotype or the pan-cancer cohort (Methods), we identified 142 significantly mutated driver genes (Fig. 2a, Supplementary Table 2, and Extended Data Fig. 3a). Somatic alterations in CDKN2A, which were predominantly deletions, occurred at the highest frequency, affecting 207 of 267 (78%) T-ALLs, 91 of 218 (42%) B-ALLs and 2 of 19 (11%) OSs (Extended Data Fig. 3b). Over half (73) of the driver genes were specific to a single histotype, such as TAL1 for T-ALL and ALK for NBL (Extended Data Fig. 3c). Genes mutated in both leukemias and the three solid tumour histotypes accounted for only 17% of driver genes (Extended Data Fig. 3e), of which some genes had various types of somatic alterations. For example, STAG2, a known driver gene for Ewing’s sarcoma14 and adult AML15, exhibited five different types of somatic alteration (SNV, indel, CNA, SV and ITD) across five histotypes (Extended Data Fig. 4a–d). Nine STAG2 variants were predicted to cause protein truncation, including four predicted by aberrant transcripts in RNA-seq. Notably, 78 of 142 driver genes (Supplementary Table 2) were not found in adult pan-cancer studies1–4, and 43 (Fig. 2a and Extended Data Fig. 3a) were not found in the Cancer Gene Census (v81)16. 37 were absent from both sources although mutations in cancer have been reported for 29 genes, such as NIPBL17–19 and LEMD320 (Extended Data Fig. 4p,q). Nearly half (40%–50%) of point mutations in leukemia and NBL driver genes had low MAFs (<0.3), indicative of subclonal mutations contributing to tumourigenesis (Extended Data Fig. 3f). 304 gene-pairs exhibited statistically significant (P<0.05, two-sided Fisher’s exact test; Fig. 2b, Supplementary Table 3) co-occurrence (e.g., USP7 and TAL1 in T-ALL21) or mutual exclusivity (e.g., MYCN and ATRX in NBL22). The analysis also unveiled novel co-occurrences (e.g., ETV6 and IKZF1 in AML and CREBBP and EP300 in B-ALL) and mutual exclusivities (e.g., SHANK2 and MYCN in NBL and PAX5 and TP53 in B-ALL). Because of reduced power for detecting low-frequency drivers2 (detection limits were 1% for the entire cohort and 3% for individual histotypes with >200 samples; Extended Data Fig. 5 and Methods), we performed subnetwork analyses3 and variant pathogenicity classification23 (Methods) and identified 184 variants in 82 additional genes (Supplementary Table 4 and Extended Data Fig. 4e–f). A notable example is the MAP3K4 G1366R mutation present in one T-ALL, two B-ALLs, and one WT. MAP3K4 is a member of the MAPK family24 and structural modeling indicates that G1366R is likely to cause disruption of normal inhibitory domain binding and kinase dynamics24 (Extended Data Fig. 4l,m). Several example SVs (PDGFRA, CDK4, YAP1, UBTF) are listed in Extended Data Fig. 4. While the percentage of tumours with point mutations in driver genes was highly consistent between WGS and WES (Fig. 3a), WGS makes it possible to detect CNAs and SVs, which are frequently driver events for pediatric cancers. For example, 72% of NBL tumours analyzed by WGS had at least one driver variant compared to 26% of those analyzed by WES (Fig. 3a and Extended Data Fig. 4j–k). Furthermore, integrative analyses of CNAs

Read the complete text